about
Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connectionJAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosisLestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disordersCirculating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic InterestGenetics of myeloproliferative neoplasmsJAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerationsMouse models of myeloproliferative neoplasms: JAK of all gradesRescue of a primary myelofibrosis model by retinoid-antagonist therapyHigh frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosisRadiation-induced erythroleukemia in the beagle dog. A hematologic summary of five cases.Myeloproliferative disease complicated by megaloblastic anemia and hyperuricemia2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and TPathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.Bone marrow fibrosis in acute lymphoblastic leukaemia of childhood.Lnk constrains myeloproliferative diseases in mice.Activation of JAK2-V617F by components of heterodimeric cytokine receptorsDifferential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cellsSurvival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells.HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansEvidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosisThe mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.Acute myelofibrosis in children with Down's syndrome.Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factorRecent advances in the bcr-abl negative chronic myeloproliferative diseases.The glycogen content of human leukocytes in health and in various disease states.THE LEUKEMIAS.Polycythemia vera: its course and treatment; relation to myeloid metaplasia and leukemiaMolecular insights into regulation of JAK2 in myeloproliferative neoplasmsBCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.Myeloproliferative syndrome presenting as neutrophilic leukaemia.JAK2 V617F: a single mutation in the myeloproliferative group of disordersX-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesExpression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model[2 further cases of familial erythremia: association of erythremia and a malignant blood disease]Light-chain disease (hypogammaglobulinemia and Bence Jones proteinuria) and sideroblastic anemia--preleukemic chronic granulocytic leukemia.
P2860
Q24607513-4B2B55F9-2C7E-48FD-93BE-F718AE8B1695Q24609999-7A380DA2-08DA-49D2-BD48-42280CCB0D01Q24657681-EDDDD039-30A8-4CAE-9FFF-ECE268987A16Q26777398-0CD7B084-65D9-4A3F-9159-02BE06611E67Q26823651-EBD39B70-21CD-4289-9268-3C573EA265B1Q27012572-4158D537-F4BC-4005-BD47-6681E758F9BBQ28078404-63D66E91-35C8-451D-8825-C3D019F58F0FQ28744478-20E557FF-8299-46AD-9AB0-874CC2827C86Q30557756-AAC74C5F-7F2D-49CC-BE3B-AFFACFA84218Q33393259-7551A435-7BE1-4535-85FD-CDEFF9187A7BQ33428539-D3E3BE80-BE09-443C-9B7B-FF1AB27677D9Q33474121-8565D1DF-003F-48D6-AFDA-1EF07F403DCBQ33572605-3B0F1FB9-317E-4A68-91C4-72940DFC9389Q33753094-F13B60FC-CC53-4DF2-BE02-311BAE79F162Q33846267-6D6B4A93-C8C7-4C0E-B714-B020878443D7Q33882944-48D3A490-7370-4EFC-AFA6-E87A095D88D6Q33883366-12C73C8C-EECA-47E2-8771-C863A03B8CBBQ33894805-D2E8A06D-9BD4-4FA7-96EB-1A4B3A3C2F16Q34037065-EB0A3963-5710-4E10-92E9-8CE3C61EC9FAQ34046864-9B309D53-4AF4-4820-913F-151ACEA2FFB1Q34162151-44108181-529F-4786-B86A-CAB41E9DF6EFQ34247430-684DB43C-3E1B-4D57-B242-38084BBCED57Q34467863-8032BFD7-1CBC-4B4E-A157-A00F81C4F8A1Q34485103-C0996A66-C38A-48BF-B502-06E849470762Q34770384-08B9632C-925D-4EE0-A8E4-AE84A5E0198AQ34985397-9F9B869C-CA75-46EB-A8FA-4A73EF066B6EQ35053286-E447D750-CB23-45EF-B28C-23C3B2453D99Q35126938-50E538CB-5F80-41DD-B276-9839CF0139DBQ35249565-CFA99A21-73C4-4B41-A701-F843EBC22920Q35450384-F5E9BDB8-6943-4C9B-ADF8-36A5ACB7FBB1Q35649626-B41742FA-966D-491F-A230-19C87CE8D874Q35661987-C6F618FC-FBA0-4822-8997-78E36C5FC29AQ35695726-0B81FC8C-6770-4549-8142-FC307B5A63FBQ35794415-727135FF-6B4B-4179-ABAE-F857FD5FB0DEQ35838146-730EAB6A-4275-4192-825A-924540E1D678Q35841611-8EF5DA93-8A18-44DB-BBE7-1C6C586E05E7Q35848319-A13CC5EB-E30A-4636-9F85-6CE28ED90B54Q35849674-A65F4F7C-A0EB-40B7-9D52-1DC020C0706CQ35920053-DC20C387-BD00-41F3-B768-BD3493B786BFQ35926330-803D33E4-0561-447E-AFFE-4738C7A5EAD5
P2860
description
1951 nî lūn-bûn
@nan
1951 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1951 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1951年の論文
@ja
1951年論文
@yue
1951年論文
@zh-hant
1951年論文
@zh-hk
1951年論文
@zh-mo
1951年論文
@zh-tw
1951年论文
@wuu
name
Some speculations on the myeloproliferative syndromes.
@ast
Some speculations on the myeloproliferative syndromes.
@en
Some speculations on the myeloproliferative syndromes.
@nl
type
label
Some speculations on the myeloproliferative syndromes.
@ast
Some speculations on the myeloproliferative syndromes.
@en
Some speculations on the myeloproliferative syndromes.
@nl
prefLabel
Some speculations on the myeloproliferative syndromes.
@ast
Some speculations on the myeloproliferative syndromes.
@en
Some speculations on the myeloproliferative syndromes.
@nl
P1433
P1476
Some speculations on the myeloproliferative syndromes
@en
P2093
W DAMESHEK
P304
P407
P577
1951-04-01T00:00:00Z